Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.39 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | LATS1 | O95835 | 1/20 | 0.33 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18922336 | 0.87 | F2 (0.41) | F2CTSDFDPSADRA2BKCNH2 | |
| SCHEMBL11478052 | 0.82 | CTSD (0.41) | F2CTSDFDPSADRA2BRAB9A | |
| SCHEMBL2128107 | 0.82 | F2 (0.41) | F2CTSDFDPSADRA2BKCNH2 | |
| SCHEMBL20626603 | 0.81 | MAPT (0.50) | MAPTL3MBTL1HRH3KMT2A | |
| SCHEMBL20112844 | 0.77 | F2 (0.39) | F2CTSDLIMK1TRPA1MAPT | |
| SCHEMBL26941343 | 0.77 | ADRA2B (0.36) | F2ADRA2BKCNH2GRIN2BRAB9A | |
| SCHEMBL7054279 | 0.76 | LIMK1 (0.51) | F2CTSDFDPSADRA2BKCNH2 | |
| SCHEMBL19669165 | 0.76 | F2 (0.40) | F2CTSDFDPSADRA2BKCNH2 | |
| SCHEMBL2128482 | 0.72 | KDM6B (0.47) | F2CTSDLIMK1MAPTLATS1 | |
| SCHEMBL19826267 | 0.71 | GAA (0.41) | RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172858-B2 | Combination pharmaceutical compositions and uses thereof | INTELLIKINE LLC (US) | 2019-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172858-B2 | Combination pharmaceutical compositions and uses thereof | CDC25C, CCNC, CDC25B | F2 4410/4885CTSD 3502/4885FDPS 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.